Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novartis AG (NYSE:NVS)

83.02
Delayed Data
As of 4:02pm ET
 +0.26 / +0.31%
Today’s Change
66.93
Today|||52-Week Range
86.90
+13.98%
Year-to-Date
Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why
10:28am / Zacks.com - Paid Partner Content
Can Ligand's Captisol Deals Boost Growth in the Long Run?
Aug 15 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Op...
Aug 18 / Zacks.com - Paid Partner Content
Are Amgen's New Drugs Doing Well Enough to Drive Sales?
Aug 15 / Zacks.com - Paid Partner Content
European Pharma Companies Slip on MS Pricing Probe
Aug 18 / TheStreet.com - Paid Partner Content
The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
Aug 10 / Zacks.com - Paid Partner Content
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Aug 17 / Zacks.com - Paid Partner Content
Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up
Aug 09 / Zacks.com - Paid Partner Content
Ophthotech's Fovista Combo Regimen Disappoints in Phase III
Aug 16 / Zacks.com - Paid Partner Content
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
Aug 08 / Zacks.com - Paid Partner Content
Catalyst (CPRX) Focused on Development of Pipeline Candidates
Aug 15 / Zacks.com - Paid Partner Content